Medicine and Dentistry
Nodular Melanoma
100%
Overall Survival
32%
Small Cell Lung Cancer
32%
Diseases
29%
Metastatic Melanoma
25%
Ipilimumab
23%
Radiation Therapy
21%
Pembrolizumab
21%
Neoplasm
20%
Immunotherapy
15%
Cutaneous Melanoma
15%
Nivolumab
15%
Progression Free Survival
14%
Carboplatin
14%
Placebo
13%
Immune Checkpoint Inhibitor
13%
Arm
13%
Malignant Neoplasm
12%
Melanoma Cell
10%
Dacarbazine
10%
Etoposide
10%
CTLA-4
9%
Adverse Event
9%
Lung Cancer
9%
Systemic Therapy
8%
Non Small Cell Lung Cancer
7%
Recurrent Disease
7%
Hazard Ratio
7%
Survival Rate
7%
Ifosfamide
6%
Recurrence Free Survival
6%
Vincristine
6%
Meta-Analysis
6%
Immune-Related Adverse Events
6%
Brain Metastasis
6%
Adjuvant Therapy
6%
Metastatic Carcinoma
6%
Mucosal Melanoma
6%
Prognostic Factor
6%
Biological Marker
6%
T Cell
6%
Cisplatin
6%
Interferon
5%
Sodium Fluoride
5%
Symptom
5%
Merkel Cell Carcinoma
5%
Vemurafenib
5%
Circulating Tumor Cell
5%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
89%
Overall Survival
35%
Small Cell Lung Cancer
29%
Chemotherapy
29%
Ipilimumab
26%
Disease
26%
Metastatic Melanoma
23%
Pembrolizumab
21%
Malignant Neoplasm
17%
Carboplatin
15%
Progression Free Survival
14%
Dacarbazine
13%
Etoposide
13%
Placebo
12%
Non Small Cell Lung Cancer
11%
Neoplasm
11%
Adverse Event
11%
Nivolumab
10%
Recurrent Disease
8%
Cisplatin
8%
Ifosfamide
8%
Lung Cancer
7%
Immune Checkpoint Inhibitor
7%
Survival Rate
7%
Immunotherapy
7%
Vemurafenib
7%
Temozolomide
7%
Interferon
7%
Recurrence Free Survival
6%
Docetaxel
6%
Brain Metastasis
6%
Cytotoxic T Lymphocyte Antigen 4
6%
Lactate Dehydrogenase
6%
Solid Malignant Neoplasm
6%
Vincristine
5%
Bevacizumab
5%
Amrubicin
5%